Veradermics Earnings Call Transcripts
Fiscal Year 2026
-
Strong phase II/III results for an extended-release oral minoxidil tablet show rapid, consistent hair growth and high tolerability in male pattern hair loss, with female trials underway. Market research reveals high unmet need and willingness to adopt, especially among women.
-
Pattern hair loss affects 80 million in the U.S., with significant unmet need and dissatisfaction with current treatments. Recent clinical trial data show strong efficacy and safety for a new oral therapy, with high adoption intent among physicians and patients. Upcoming milestones include additional male and first female data releases.
-
Top-line results from a large phase II/III trial show VDPHL01 achieved significant hair growth and high patient satisfaction with a strong safety profile. Both once- and twice-daily regimens outperformed existing therapies, and market research indicates high intent to prescribe and use if approved.
-
A novel extended-release oral minoxidil tablet is advancing through phase III trials, showing rapid and robust hair growth with improved safety and convenience. The product targets a large, motivated market, leverages a strong IP portfolio, and is positioned for broad adoption through dermatology, primary care, and telehealth channels.